• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    MetLife Launches Cancer Support Benefit to Help Employees Understand and Navigate Care Options as Cancer Diagnoses Continue to Rise

    9/4/25 9:00:00 AM ET
    $MET
    Life Insurance
    Finance
    Get the next $MET alert in real time by email

    Through a strategic collaboration with Private Health Management, new offering provides individuals with expert-guided cancer education and financial support

    MetLife has introduced a new Cancer Support benefit to help employees with personalized advice and attention from diagnosis to treatment and through recovery. Through a strategic relationship with Private Health Management, a leader in complex care navigation, MetLife will expand its Critical Illness Insurance offering to provide a more robust cancer benefit, including access to top oncology specialists, tech-enabled and expert-led coordination, and patient counseling – all of which help to provide a clearer path forward for patients. This announcement comes as new cases of cancer are anticipated to rise to more than two million in 2025.1

    "Our new Cancer Support benefit raises the bar in delivering compassionate, expert-led guidance at a time when individuals are facing one of life's most difficult moments," said Chris Swanker, senior vice president, Group Benefits Products at MetLife. "For employers, it's a meaningful way to support their employees, offering a benefit that can make a difference in how they navigate the complexities of a cancer diagnosis and improve patient outcomes. As cancer costs continue to rise, this benefit also has been proven to reduce overall medical costs for employees and employers alike."

    One in every three Americans will develop cancer in their lifetime,1 and those impacted by cancer are 71% more likely to face financial hardship within two years of diagnosis.2 Cancer is one of the most expensive medical conditions to treat, with total costs projected to rise 34% between 2015 and 2030.2

    As part of the collaboration, Private Health Management's team of experienced professionals will work closely with MetLife to ensure that covered policyholders receive individualized counseling and attention, helping them navigate the complexities of cancer treatment and recovery. Employers who have deployed Private Health Management services have seen strong outcomes,3 including:

    - 20% reduction in average cost per case managed

    - 15% avoided unnecessary treatments

    - 30% received redefined/changed diagnoses

    - 70% saw modification of treatment plans for optimal care

    - 2-4 times improvement in survival for late-stage cancers

    "MetLife is building a truly comprehensive benefits experience – adding a Cancer Support benefit will be a critical element," said Ken Tarkoff, CEO of Private Health Management. "At Private Health Management, our mission is to empower patients with the knowledge, resources, and support they need to achieve the best possible outcomes. We are excited to team up with MetLife to bring that promise to more patients in their cancer treatment and recovery journeys."

    MetLife's Cancer Support benefit will be available to MetLife Critical Illness insureds with covered cancer conditions, beginning January 1, 2026. To learn more about MetLife's Critical Illness Insurance and Cancer Support benefit, visit our website or email directly.

    About MetLife

    MetLife, Inc. (NYSE:MET), through its subsidiaries and affiliates ("MetLife"), is one of the world's leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Asia, Latin America, Europe and the Middle East. For more information, visit www.metlife.com.

    About PHM

    Private Health Management (PHM) is a clinically sophisticated complex care management company that provides guidance for individuals facing serious medical conditions like cancer. PHM connects clients with top specialists, cutting-edge diagnostics, and personalized, science-backed treatment plans to achieve the best possible care. Independent and trusted by leading employers and providers alike, PHM helps individuals make confident decisions that lead to better outcomes. Learn more at www.privatehealth.com.

    Citations:

    1. American Cancer Society, "Cancer Facts & Figures 2025," 2025. Cancer Facts & Figures 2025
    2. NIHCM Foundation, "Insights on Cancer: Rates, Costs, and Strategies" December 2024. Insights on Cancer: Rates, Costs, and Strategies
    3. Private Health Management. (2025, January). Improving cancer survival: PHM's impact on cancer care

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250904488273/en/

    Media Contact:

    Liz Harish

    929-343-7473

    [email protected]

    Get the next $MET alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MET

    DatePrice TargetRatingAnalyst
    1/23/2025$97.00Market Perform
    BMO Capital Markets
    10/9/2024$97.00Buy
    TD Cowen
    9/5/2024$91.00Overweight
    Barclays
    1/8/2024$80.00Neutral → Buy
    Goldman
    11/17/2023$71.00Overweight
    Barclays
    10/5/2023$71.00Hold
    Deutsche Bank
    9/14/2023$58.00 → $72.00Hold → Buy
    Jefferies
    1/9/2023$80.00 → $78.00Buy → Neutral
    Goldman
    More analyst ratings

    $MET
    SEC Filings

    View All

    SEC Form 8-K filed by MetLife Inc.

    8-K - METLIFE INC (0001099219) (Filer)

    9/2/25 4:26:54 PM ET
    $MET
    Life Insurance
    Finance

    SEC Form N-PX filed by MetLife Inc.

    N-PX - METLIFE INC (0001099219) (Filer)

    9/2/25 4:07:31 PM ET
    $MET
    Life Insurance
    Finance

    MetLife Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - METLIFE INC (0001099219) (Filer)

    8/15/25 4:21:47 PM ET
    $MET
    Life Insurance
    Finance

    $MET
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MetLife Launches Cancer Support Benefit to Help Employees Understand and Navigate Care Options as Cancer Diagnoses Continue to Rise

    Through a strategic collaboration with Private Health Management, new offering provides individuals with expert-guided cancer education and financial support MetLife has introduced a new Cancer Support benefit to help employees with personalized advice and attention from diagnosis to treatment and through recovery. Through a strategic relationship with Private Health Management, a leader in complex care navigation, MetLife will expand its Critical Illness Insurance offering to provide a more robust cancer benefit, including access to top oncology specialists, tech-enabled and expert-led coordination, and patient counseling – all of which help to provide a clearer path forward for patients

    9/4/25 9:00:00 AM ET
    $MET
    Life Insurance
    Finance

    MetLife Announces Full Redemption of Series G Preferred Stock

    Full Redemption of 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G MetLife, Inc. (NYSE:MET) today announced that it will redeem all outstanding shares of its 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, liquidation preference of $1,000 per share ("Series G Preferred Stock"), at a redemption price of $1,000 per share of Series G Preferred Stock. All outstanding shares of Series G Preferred Stock will be redeemed on the dividend payment date of September 15, 2025. Regular dividends on the outstanding shares of Series G Preferred Stock of $19.250 per share will be paid separately on September 15, 2025, to holders of record as of the close of business o

    9/2/25 4:15:00 PM ET
    $MET
    Life Insurance
    Finance

    MetLife Investment Management Names Geert Henckens Global Head of Private Fixed Income

    MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE:MET), today announced that it has named Geert Henckens global head of Private Fixed Income. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250821742408/en/Geert Henckens, MetLife Investment Management Henckens will expand his role to lead teams that originate and manage a broad array of private asset investments that aim to offer clients attractive relative value, portfolio diversification and potential downside protection. MIM has a longstanding track record of originating and managing private assets and originated $21.6 bill

    8/21/25 4:15:00 PM ET
    $MET
    Life Insurance
    Finance

    $MET
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hubbard Robert Glenn was granted 663 shares, increasing direct ownership by 0.66% to 101,151 units (SEC Form 4)

    4 - METLIFE INC (0001099219) (Issuer)

    9/11/25 4:02:44 PM ET
    $MET
    Life Insurance
    Finance

    Director Harris Carla A was granted 30 shares, increasing direct ownership by 0.35% to 8,514 units (SEC Form 4)

    4 - METLIFE INC (0001099219) (Issuer)

    9/11/25 4:02:30 PM ET
    $MET
    Life Insurance
    Finance

    Director Mckenzie Diana was granted 158 shares, increasing direct ownership by 0.72% to 22,223 units (SEC Form 4)

    4 - METLIFE INC (0001099219) (Issuer)

    9/11/25 4:02:37 PM ET
    $MET
    Life Insurance
    Finance

    $MET
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BMO Capital Markets initiated coverage on MetLife with a new price target

    BMO Capital Markets initiated coverage of MetLife with a rating of Market Perform and set a new price target of $97.00

    1/23/25 7:50:09 AM ET
    $MET
    Life Insurance
    Finance

    TD Cowen initiated coverage on MetLife with a new price target

    TD Cowen initiated coverage of MetLife with a rating of Buy and set a new price target of $97.00

    10/9/24 7:52:22 AM ET
    $MET
    Life Insurance
    Finance

    Barclays initiated coverage on MetLife with a new price target

    Barclays initiated coverage of MetLife with a rating of Overweight and set a new price target of $91.00

    9/5/24 8:14:53 AM ET
    $MET
    Life Insurance
    Finance

    $MET
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Johnson Jeh C. bought $879 worth of shares (17 units at $51.69) and was granted 19 shares, increasing direct ownership by 1% to 2,545 units (SEC Form 4)

    4 - METLIFE INC (0001099219) (Issuer)

    12/18/23 5:20:05 PM ET
    $MET
    Life Insurance
    Finance

    $MET
    Leadership Updates

    Live Leadership Updates

    View All

    MetLife Investment Management Agrees to Acquire Traditional Fixed Income and Equity Portfolio Management Teams Managing $6 Billion From Mesirow

    Acquisition includes high yield, strategic fixed income and small-cap equity teams MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE:MET), today announced that it has reached a definitive agreement to acquire three investment teams and assets managed by Mesirow, an independent, employee-owned financial services firm. MIM is acquiring the high yield and bank loan, strategic fixed income and small-cap equity teams and certain related investment products. Under the terms of the transaction, about $6 billion of assets managed by the acquired teams will transfer to MIM, subject to customary approvals and consents. The acquisition is consi

    1/8/25 8:30:00 AM ET
    $MET
    Life Insurance
    Finance

    MetLife Investment Management Names Kerry O'Brien Global Head of Insurance Asset Management and Liability Solutions

    MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE:MET), today announced that it has appointed Kerry O'Brien as global head of Insurance Asset Management and Liability Solutions. She will be responsible for the execution of investment strategies for the MetLife general account, helping drive growth in MIM's third-party insurance client channel as well as working with teams to drive liability solutions across other client segments. O'Brien will lead a team with an insurance investing heritage of nearly 150 years and an active role in managing MetLife's $414.1 billion general account as well as assets for third-party insurance clients. Sh

    12/2/24 8:30:00 AM ET
    $MET
    Life Insurance
    Finance

    MetLife Worldwide Benefits and GeoBlue® to Offer Joint Solution

    Combining the medical and ancillary strengths of two leading global carriers into a single solution -- Globaline™ MetLife and GeoBlue, the international solution for the Blue Cross® Blue Shield® companies, announced today they will offer a full suite of expatriate benefit products in a best-in-class single solution, Globaline™. Globaline™ brings together health coverage and services from GeoBlue – including medical, dental, vision, prescription, wellness, international employee assistance program and political and natural disaster assistance – and life, accidental death & dismemberment and long term disability coverage from MetLife Worldwide Benefits, including value-added services, such

    6/25/24 9:00:00 AM ET
    $MET
    Life Insurance
    Finance

    $MET
    Financials

    Live finance-specific insights

    View All

    MetLife Announces Full Redemption of Series G Preferred Stock

    Full Redemption of 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G MetLife, Inc. (NYSE:MET) today announced that it will redeem all outstanding shares of its 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, liquidation preference of $1,000 per share ("Series G Preferred Stock"), at a redemption price of $1,000 per share of Series G Preferred Stock. All outstanding shares of Series G Preferred Stock will be redeemed on the dividend payment date of September 15, 2025. Regular dividends on the outstanding shares of Series G Preferred Stock of $19.250 per share will be paid separately on September 15, 2025, to holders of record as of the close of business o

    9/2/25 4:15:00 PM ET
    $MET
    Life Insurance
    Finance

    MetLife Declares Third Quarter 2025 Preferred Stock Dividends

    MetLife, Inc. (NYSE:MET) today announced that it has declared the following preferred stock dividends: Quarterly dividend of $0.35263005 per share on the company's floating rate non-cumulative preferred stock, Series A, with a liquidation preference of $25 per share (NYSE:MET). Semi-annual dividend of $29.375 per share on the company's 5.875% fixed-to-floating rate non-cumulative preferred stock, Series D, with a liquidation preference of $1,000 per share. Quarterly dividend of $351.5625 per share on the company's 5.625% non-cumulative preferred stock, Series E, with a liquidation preference of $25,000 per share, represented by depositary shares each representing 1/1,000th interest

    8/15/25 4:15:00 PM ET
    $MET
    Life Insurance
    Finance

    MetLife Announces 2Q 2025 Results

    MetLife, Inc. (NYSE:MET) today announced its second quarter 2025 results.   Earnings       Return     Per Share       on Equity (ROE)     2Q 2025       2Q 2025                         Net Income $1.03 ROE 11.7%                       Adjusted Earnings $2.02 Adjusted ROE 14.6% Net income was $698 million. Adjusted earnings declined to $1.4 billion, due to less favorable underwriting and lower investment margins, partially offset by volume growth and favorable expense margins. Premiums, fees and other revenues (PFOs) were $12.7 billion. Adjusted

    8/6/25 4:15:00 PM ET
    $MET
    Life Insurance
    Finance

    $MET
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MetLife Inc.

    SC 13D/A - METLIFE INC (0001099219) (Subject)

    11/1/24 5:05:26 PM ET
    $MET
    Life Insurance
    Finance

    Amendment: SEC Form SC 13D/A filed by MetLife Inc.

    SC 13D/A - METLIFE INC (0001099219) (Subject)

    8/1/24 4:38:49 PM ET
    $MET
    Life Insurance
    Finance

    SEC Form SC 13D/A filed by MetLife Inc. (Amendment)

    SC 13D/A - METLIFE INC (0001099219) (Subject)

    5/2/24 5:34:57 PM ET
    $MET
    Life Insurance
    Finance